A recent study in mice showed that inhibition of PHD2 increases the HCC occurrence and stimulates the development of cholangiocarcinoma.16 However, little is known about the association between PHD2 and HCC in a clinical setting. The gene discussed is EGLN1; the disease is cholangiocarcinoma.